Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OKN-007 + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OKN-007 | OKN007|OKN 007 | OKN-007 is a small molecule nitrone inhibitor that can cross the blood brain barrier, and may result in anti-inflammatory and apoptotic activity (PMID: 26248280, PMID: 31628293). | ||
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04388475 | Phase II | OKN-007 + Temozolomide | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT03587038 | Phase I | OKN-007 + Temozolomide | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |